Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 413735, 9 pages
http://dx.doi.org/10.1155/2013/413735
Review Article

Inflammation and Immune Response in COPD: Where Do We Stand?

Intensive Care Unit, 1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 152 Mesogeion Avenue, 11527 Athens, Greece

Received 12 February 2013; Accepted 2 July 2013

Academic Editor: Helen C. Steel

Copyright © 2013 Nikoletta Rovina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. F. Rabe, S. Hurd, A. Anzueto et al., “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 6, pp. 532–555, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. W. MacNee, “Pathogenesis of chronic obstructive pulmonary disease,” Clinics in Chest Medicine, vol. 28, no. 3, pp. 479–513, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Stockley, D. Mannino, and P. J. Barnes, “Burden and pathogenesis of chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 6, no. 6, pp. 524–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. W. Ind, “COPD disease progression and airway inflammation: uncoupled by smoking cessation,” The European Respiratory Journal, vol. 26, no. 5, pp. 764–766, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Simmons, J. E. Connett, M. A. Nides et al., “Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study,” The European Respiratory Journal, vol. 25, no. 6, pp. 1011–1017, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. K. F. Chung and I. M. Adcock, “Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction,” The European Respiratory Journal, vol. 31, no. 6, pp. 1334–1356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Sharafkhaneh, N. A. Hanania, and V. Kim, “Pathogenesis of emphysema: from the bench to the bedside,” Proceedings of the American Thoracic Society, vol. 5, no. 4, pp. 475–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Taraseviciene-Stewart and N. F. Voelkel, “Molecular pathogenesis of emphysema,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 394–402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Tuder, T. Yoshida, W. Arap, R. Pasqualini, and I. Petrache, “Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective,” Proceedings of the American Thoracic Society, vol. 3, no. 6, pp. 503–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. T. Motz, B. L. Eppert, G. Sun et al., “Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema,” Journal of Immunology, vol. 181, no. 11, pp. 8036–8043, 2008. View at Google Scholar · View at Scopus
  11. G. T. Motz, B. L. Eppert, S. C. Wesselkamper, J. L. Flury, and M. T. Borchers, “Chronic cigarette smoke exposure generates pathogenic T cells capable of driving COPD-like disease in Rag2-/- mice,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 11, pp. 1223–1233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. K. Sullivan, P. L. Simonian, M. T. Falta et al., “Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema,” The American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 590–596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-H. Lee, S. Goswami, A. Grudo et al., “Antielastin autoimmunity in tobacco smoking-induced emphysema,” Nature Medicine, vol. 13, no. 5, pp. 567–569, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Barnes, S. D. Shapiro, and R. A. Pauwels, “Chronic obstructive pulmonary disease: molecular and cellular mechanisms,” The European Respiratory Journal, vol. 22, no. 4, pp. 672–688, 2003. View at Google Scholar · View at Scopus
  15. S. Baraldo, G. Turato, C. Badin et al., “Neutrophilic infiltration within the airway smooth muscle in patients with COPD,” Thorax, vol. 59, no. 4, pp. 308–312, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Comer, J. C. Kidney, M. Ennis et al., “Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers,” The European Respiratory Journal, vol. 41, no. 54, pp. 1058–1067, 2013. View at Google Scholar
  17. M. Tanino, T. Betsuyaku, K. Takeyabu et al., “Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema,” Thorax, vol. 57, no. 5, pp. 405–411, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Stǎnescu, A. Sanna, C. Veriter et al., “Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils,” Thorax, vol. 51, no. 3, pp. 267–271, 1996. View at Google Scholar · View at Scopus
  19. S. L. Traves, S. V. Culpitt, R. E. K. Russell, P. J. Barnes, and L. E. Donnelly, “Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD,” Thorax, vol. 57, no. 7, pp. 590–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. A. di Stefano, P. Maestrelli, A. Roggeri et al., “Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis,” The American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3, pp. 803–810, 1994. View at Google Scholar · View at Scopus
  21. S. D. Shapiro, “The macrophage in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5, part 2, pp. S29–S32, 1999. View at Google Scholar · View at Scopus
  22. R. Finkelstein, R. S. Fraser, H. Ghezzo, and M. G. Cosio, “Alveolar inflammation and its relation to emphysema in smokers,” The American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 5, pp. 1666–1672, 1995. View at Google Scholar · View at Scopus
  23. A. di Stefano, A. Capelli, M. Lusuardi et al., “Severity of airflow limitation is associated with severity of airway inflammation in smokers,” The American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 4, pp. 1277–1285, 1998. View at Google Scholar · View at Scopus
  24. A. Punturieri, S. Filippov, E. Allen et al., “Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages,” Journal of Experimental Medicine, vol. 192, no. 6, pp. 789–800, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. R. E. K. Russell, A. Thorley, S. V. Culpitt et al., “Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 283, no. 4, pp. L867–L873, 2002. View at Google Scholar · View at Scopus
  26. A. di Stefano, G. Caramori, T. Oates et al., “Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD,” The European Respiratory Journal, vol. 20, no. 3, pp. 556–563, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Caramori, M. Romagnoli, P. Casolari et al., “Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations,” Thorax, vol. 58, no. 4, pp. 348–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Saetta, M. Mariani, P. Panina-Bordignon et al., “Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 10, pp. 1404–1409, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Birrell and S. Eltom, “The role of the NLRP3 Inflammasome in the pathogenesis of airway disease,” Pharmacology and Therapeutics, vol. 130, no. 3, pp. 364–370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Wanderer, “Interleukin-1 β targeted therapy in severe persistent asthma (SPA) and chronic obstructive pulmonary disease (COPD): proposed similarities between biphasic pathobiology of SPA/COPD and ischemia-reperfusion injury,” Israel Medical Association Journal, vol. 10, no. 12, pp. 837–842, 2008. View at Google Scholar · View at Scopus
  31. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mitochondria in NLRP3 inflammasome activation,” Nature, vol. 469, no. 7329, pp. 221–225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. K. J. Ishii, S. Koyama, A. Nakagawa, C. Coban, and S. Akira, “Host innate immune receptors and beyond: making sense of microbial infections,” Cell Host and Microbe, vol. 3, no. 6, pp. 352–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Opitz, V. van Laak, J. Eitel, and N. Suttorp, “Innate immune recognition in infectious and noninfectious diseases of the lung,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 12, pp. 1294–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Franchi, C. McDonald, T.-D. Kanneganti, A. Amer, and G. Núñez, “Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense,” Journal of Immunology, vol. 177, no. 6, pp. 3507–3513, 2006. View at Google Scholar · View at Scopus
  35. T. Maes, K. R. Bracke, K. Y. Vermaelen et al., “Murine TLR4 is implicated in cigarette smoke-induced pulmonary inflammation,” International Archives of Allergy and Immunology, vol. 141, no. 4, pp. 354–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Doz, N. Noulin, E. Boichot et al., “Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent,” Journal of Immunology, vol. 180, no. 2, pp. 1169–1178, 2008. View at Google Scholar · View at Scopus
  37. C. M. Freeman, F. J. Martinez, M. K. Han et al., “Lung CD8+ T cells inCOPD have increased expression of bacterial TLRs,” Respiratory Research, vol. 1, no. 14, article 13, 2013. View at Google Scholar
  38. D. Perregaux and C. A. Gabel, “Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity,” Journal of Biological Chemistry, vol. 269, no. 21, pp. 15195–15203, 1994. View at Google Scholar · View at Scopus
  39. Y. Qu, L. Franchi, G. Nunez, and G. R. Dubyak, “Nonclassical IL-1β secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages,” Journal of Immunology, vol. 179, no. 3, pp. 1913–1925, 2007. View at Google Scholar · View at Scopus
  40. S. Eltom, C. S. Stevenson, J. Rastrick et al., “P2x7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke,” PLoS ONE, vol. 6, no. 9, Article ID e24097, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Mariathasan and D. M. Monack, “Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation,” Nature Reviews Immunology, vol. 7, no. 1, pp. 31–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. F. S. Sutterwala, Y. Ogura, D. S. Zamboni, C. R. Roy, and R. A. Flavell, “NALP3: a key player in caspase-1 activation,” Journal of Endotoxin Research, vol. 12, no. 4, pp. 251–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. R. Lazarowski, R. C. Boucher, and T. K. Harden, “Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules,” Molecular Pharmacology, vol. 64, no. 4, pp. 785–795, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. S. C. Robson, E. Kaczmarek, J. B. Siegel et al., “Loss of ATP diphosphohydrolase activity with endothelial cell activation,” Journal of Experimental Medicine, vol. 185, no. 1, pp. 153–163, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Mohsenin and M. R. Blackburn, “Adenosine signaling in asthma and chronic obstructive pulmonary disease,” Current Opinion in Pulmonary Medicine, vol. 12, no. 1, pp. 54–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Polosa and M. R. Blackburn, “Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease,” Trends in Pharmacological Sciences, vol. 30, no. 10, pp. 528–535, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Lommatzsch, S. Cicko, T. Müller et al., “Extracellular adenosine triphosphate and chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 9, pp. 928–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Cicko, M. Lucattelli, T. Müller et al., “Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema,” Journal of Immunology, vol. 185, no. 1, pp. 688–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Mortaz, S. Braber, M. Nazary, M. E. Givi, F. P. Nijkamp, and G. Folkerts, “ATP in the pathogenesis of lung emphysema,” The European Journal of Pharmacology, vol. 619, no. 1–3, pp. 92–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Ferhani, S. Letuve, A. Kozhich et al., “Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 9, pp. 917–927, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Hou, H. Zhao, L. Liu et al., “High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls,” Molecular Medicine, vol. 17, no. 7-8, pp. 807–815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. C. M. Wang, M. Jiang, and H. J. Wang, “Effect of NF-κB inhibitor on high-mobility group protein B1 expression in a COPD rat model,” Medical Representative, vol. 7, no. 2, pp. 499–502, 2013. View at Google Scholar
  53. S. Mitola, M. Belleri, C. Urbinati et al., “Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine,” Journal of Immunology, vol. 176, no. 1, pp. 12–15, 2006. View at Google Scholar · View at Scopus
  54. M. B. Sukkar, L. G. Wood, M. Tooze et al., “Soluble RAGE is deficient in neutrophilic asthma and COPD,” The European Respiratory Journal, vol. 39, no. 3, pp. 721–729, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Kanazawa, Y. Tochino, K. Asai, Y. Ichimaru, T. Watanabe, and K. Hirata, “Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD,” The European Journal of Clinical Investigation, vol. 42, no. 4, pp. 419–426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. T. L. Adair-Kirk, J. J. Atkinson, and R. M. Senior, “Smoke particulates stress lung cells,” Nature Medicine, vol. 14, no. 10, pp. 1024–1025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Churg, S. Zhou, X. Wang, R. Wang, and J. L. Wright, “The role of lnterleukin-1 p in murine cigarette smoke-induced emphysema and small airway remodeling,” The American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 4, pp. 482–490, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. M.-J. Kang, R. J. Homer, A. Gallo et al., “IL-18 is induced and IL-18 receptor α plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation,” Journal of Immunology, vol. 178, no. 3, pp. 1948–1959, 2007. View at Google Scholar · View at Scopus
  59. E. C. Lucey, J. Keane, P.-P. Kuang, G. L. Snider, and R. H. Goldstein, “Severity of elastase-induced emphysema is decreased in tumor necrosis factor-α and interleukin-1β receptor-deficient mice,” Laboratory Investigation, vol. 82, no. 1, pp. 79–85, 2002. View at Google Scholar · View at Scopus
  60. S. Eltom, C. S. Stevenson, J. Rastrick et al., “The role of the inflammasome in cigarette smoke-induced inflammation,” Proceedings of the British Pharmacological Socitey, vol. 8, p. 149, 2010. View at Google Scholar
  61. B. Singh, S. Arora, and V. Khanna, “Association of severity of COPD with IgE and interleukin-1beta,” Monaldi Archives for Chest Disease, vol. 73, no. 2, pp. 86–87, 2010. View at Google Scholar · View at Scopus
  62. M. Singh, S.-H. Lee, P. Porter et al., “Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease,” Journal of Allergy and Clinical Immunology, vol. 125, no. 6, pp. 1369.e2–1378.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. U. Lappalainen, J. A. Whitsett, S. E. Wert, J. W. Tichelaar, and K. Bry, “Interleukin-1β causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung,” The American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 4, pp. 311–318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. F. M. Botelho, C. M. T. Bauer, D. Finch et al., “IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice,” PLoS ONE, vol. 6, no. 12, Article ID e28457, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. F. M. Botelho, J. K. Nikota, C. M. Bauer et al., “Cigarette smoke-induced accumulation of lung dendritic cells is interleukin-1alpha-dependent in mice,” Respiratory Research, vol. 13, article 81, 2012. View at Google Scholar
  66. N. S. Pauwels, K. R. Bracke, L. L. Dupont et al., “Role of IL-1α and the Nlrp3/caspase-1/IL-1βaxis in cigarette smoke-induced pulmonary inflammation and COPD,” The European Respiratory Journal, vol. 38, no. 5, pp. 1019–1028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. A. M. W. Petersen, M. Penkowa, M. Iversen et al., “Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease,” Lung, vol. 185, no. 3, pp. 161–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Imaoka, T. Hoshino, S. Takei et al., “Interleukin-18 production and pulmonary function in COPD,” The European Respiratory Journal, vol. 31, no. 2, pp. 287–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Rovina, E. Dima, C. Gerassimou, A. Kollintza, C. Gratziou, and C. Roussos, “Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 103, no. 7, pp. 1056–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Rovina, E. Dima, C. Gerassimou, A. Kollintza, C. Gratziou, and C. Roussos, “IL-18 in induced sputum and airway hyperresponsiveness in mild asthmatics: effect of smoking,” Respiratory Medicine, vol. 103, no. 12, pp. 1919–1925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Wang, X. Liu, M. Xie et al., “Increased expression ofinterleukin-18 and its receptor in peripheral blood of patients withchronic obstructive pulmonary disease,” COPD, vol. 9, no. 4, pp. 375–381, 2012. View at Google Scholar
  72. M. J. Kang, J. M. Choi, B. H. Kim et al., “IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13,” The American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 11, pp. 1205–1217, 2012. View at Google Scholar
  73. J. Wang, X. Liu, J. Xie et al., “Association ofinterleukin-18 promoter polymorphisms withchronic obstructive pulmonary disease in male smokers,” International Journal of Immunogenetics, vol. 40, no. 3, pp. 204–208, 2013. View at Google Scholar
  74. A. Kratzer, J. Salys, C. Nold-Petry et al., “Role of IL-18 in second-hand smoke-induced emphysema,” The American Journal of Respiratory Cell and Molecular Biology, vol. 48, no. 6, pp. 725–732, 2013. View at Google Scholar
  75. T. Hoshino, S. Kato, N. Oka et al., “Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 1, pp. 49–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. M. G. Cosio, M. Saetta, and A. Agusti, “Immunologic aspects of chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2396–2454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Saetta, A. di Stefano, G. Turato et al., “CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 3, pp. 822–826, 1998. View at Google Scholar · View at Scopus
  78. J. C. Hogg, F. Chu, S. Utokaparch et al., “The nature of small-airway obstruction in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2645–2653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Proklou, N. Soulitzis, E. Neofytou et al., “Granule cytotoxic activity and oxidative DNA damage in smoking and non-smoking asthmatics,” Chest, 2013. View at Publisher · View at Google Scholar
  80. W. D. Kim, H. S. Chi, K. H. Choe et al., “A possible role for CD8+ and non-CD8+ cell granzyme B in early small airway wall remodelling in centrilobular emphysema,” Respirology, vol. 18, no. 4, pp. 688–696, 2013. View at Google Scholar
  81. G. Hodge, M. Holmes, H. Jersmann et al., “The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD,” Respiratory Research, vol. 14, article 63, 2013. View at Google Scholar
  82. R. A. Urbanowicz, J. R. Lamb, I. Todd, J. M. Corne, and L. C. Fairclough, “Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients,” Respiratory Research, vol. 11, article 76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. A. di Stefano, G. Caramori, I. Gnemmi et al., “T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients,” Clinical and Experimental Immunology, vol. 157, no. 2, pp. 316–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Grumelli, D. B. Corry, L.-Z. Song et al., “An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema,” PLoS Medicine, vol. 1, no. 1, article e8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Miossec, T. Korn, and V. K. Kuchroo, “Interleukin-17 and type 17 helper T cells,” The New England Journal of Medicine, vol. 361, no. 9, pp. 848–898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. Q. Tang and J. A. Bluestone, “The Foxp3+ regulatory T cell: a jack of all trades, master of regulation,” Nature Immunology, vol. 9, no. 3, pp. 239–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. G. G. Brusselle, T. Demoor, K. R. Bracke, C.-A. Brandsma, and W. Timens, “Lymphoid follicles in (very) severe COPD: beneficial or harmful?” The European Respiratory Journal, vol. 34, no. 1, pp. 219–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. B. W. A. van der Strate, D. S. Postma, C.-A. Brandsma et al., “Cigarette smoke-induced emphysema: a role for the B cell?” The American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 751–758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Litsiou, M. Semitekolou, I. E. Galani et al., “CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 11, pp. 1194–1202, 2013. View at Google Scholar
  90. K. R. Bracke, F. M. Verhamme, L. J. Seys et al., “Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and COPD,” American Journal of Respiratory and Critical Care Medicine. In press.
  91. B. Nunez, J. Sauleda, J. M. Anto et al., “Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 8, pp. 1025–1031, 2011. View at Google Scholar
  92. C. M. Greene, T. B. Low, S. J. O'Neill, and N. G. McElvaney, “Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 1, pp. 31–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. A. M. Wood, P. de Pablo, C. D. Buckley, A. Ahmad, and R. A. Stockley, “Smoke exposure as a determinant of autoantibody titre in α1-antitrypsin deficiency and COPD,” The European Respiratory Journal, vol. 37, no. 1, pp. 32–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Rinaldi, A. Lehouck, N. Heulens et al., “Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease,” Thorax, vol. 67, no. 8, pp. 694–700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. H. P. J. Bonarius, C. A. Brandsma, H. A. M. Kerstjens et al., “Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history,” Thorax, vol. 66, no. 2, pp. 101–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Sethi and T. F. Murphy, “Infection in the pathogenesis and course of chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 359, no. 22, pp. 2355–2365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Rossel, E. Monso, N. Soler et al., “Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease,” Archives of Internal Medicine, vol. 165, no. 8, pp. 891–897, 2005. View at Google Scholar
  98. L. Dethlefsen, M. McFall-Ngai, and D. A. Relman, “An ecological and evolutionary perspective on humang-microbe mutualism and disease,” Nature, vol. 449, no. 7164, pp. 811–818, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. E. S. Charlson, K. Bittinger, A. R. Haas et al., “Topographical continuity of bacterial populations in the healthy human respiratory tract,” The American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 8, pp. 957–963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. E. S. Charlson, K. Bittinger, J. Chen et al., “Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts,” PLoS One, vol. 7, no. 9, Article ID e42786, 2012. View at Google Scholar
  101. M. A. Sze, P. A. Dimitriu, S. Hayashi et al., “The lung tissue microbiome inchronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 10, pp. 1073–1080, 2012. View at Google Scholar
  102. A. A. Pragman, H. B. Kim, C. S. Reilly et al., “The lung microbiome in moderate and severechronic obstructive pulmonary disease,” PLoS One, vol. 7, no. 10, Article ID e47305, 2012. View at Google Scholar
  103. M. K. Han, Y. J. Huang, J. J. LiPuma et al., “Significance of the microbiome in obstructive lung disease,” Thorax, vol. 67, no. 5, pp. 456–463, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. J. R. Erb-Downward, D. L. Thompson, M. K. Han et al., “Analysis of the lung microbiome in the “Healthy” smoker and in COPD,” PLoS One, vol. 6, no. 2, Article ID e16384, 2011. View at Google Scholar
  105. Y. J. Huang and S. V. Lynch, “The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications,” Expert Review of Respiratory Medicine, vol. 5, no. 6, pp. 809–821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Mallia, S. D. Message, V. Gielen et al., “Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation,” The American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 734–742, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. B. Levine, N. Mizushima, and H. W. Virgin, “Autophagy in immunity and inflammation,” Nature, vol. 469, no. 7330, pp. 323–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. C. A. Feghali-Bostwick, A. S. Gadgil, L. E. Otterbein et al., “Autoantibodies in patients with chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 2, pp. 156–163, 2008. View at Publisher · View at Google Scholar · View at Scopus